dataOvarian: Advanced Ovarian Cancer dataset

In frailtypack: Shared, Joint (Generalized) Frailty Models; Surrogate Endpoints

Advanced Ovarian Cancer dataset

Description

This dataset combines the data that were collected in four double-blind randomized clinical trials in advanced ovarian cancer. In these trials, the objective was to examine the efficacy of cyclophosphamide plus cisplatin (CP) versus cyclophosphamide plus adriamycin plus cisplatin (CAP) to treat advanced ovarian cancer. The candidate surrogate endpoint S is progression-free survival time, defined as the time (in years) from randomization to clinical progression of the disease or death. The true endpoint T is survival time, defined as the time (in years) from randomization to death of any cause

Usage

data(dataOvarian)

Format

This data frame contains the following columns:

patientID

The identification number of a patient

trialID

The center in which a patient was treated

trt

The treatment indicator, coded as 0 = cyclophosphamide plus cisplatin (CP) and 1 = cyclophosphamide plus adriamycin plus cisplatin(CAP)

timeS

The candidate surrogate (progression-free survival)

statusS

Censoring indicator for for Progression-free survival

timeT

The true endpoint (survival time)

statusT

Censoring indicator for survival time

Source

Ovarian cancer Meta-Analysis Project (1991). Cyclophosphamide plus cisplatin plus adriamycin versus Cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. Classic Papers and Current Comments, 3, 237-234.

frailtypack documentation built on Nov. 25, 2023, 9:06 a.m.